Engineered donor cells take on tough leukemia
Disease control
Recruiting now
This study tests a new treatment called UCART22 for people with a type of blood cancer (B-cell acute lymphoblastic leukemia) that has come back or not responded to standard therapy. UCART22 uses donor immune cells that are engineered to recognize and attack cancer cells carrying …
Phase: PHASE1, PHASE2 • Sponsor: Cellectis S.A. • Aim: Disease control
Last updated May 01, 2026 15:58 UTC